Dr. Reddy’s (NYSE: RDY) North America CEO reports 47,325 ADR shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
DR REDDYS LABORATORIES LTD executive Milan Kantilal Kalawadia, CEO – North America, has filed an initial Form 3 reporting his ownership in the company. The filing lists 47,325 Equity Shares underlying ADRs held with direct ownership, and does not report any recent purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
KALAWADIA MILAN KANTILAL
Role
CEO - North America
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Equity Shares underlying ADRs | -- | -- | -- |
Holdings After Transaction:
Equity Shares underlying ADRs — 47,325 shares (Direct)
Footnotes (1)
Key Figures
Directly owned shares: 47,325 Equity Shares underlying ADRs
1 metrics
Directly owned shares
47,325 Equity Shares underlying ADRs
Beneficial ownership reported on Form 3
Key Terms
Form 3, Equity Shares underlying ADRs, beneficial ownership
3 terms
Form 3 regulatory
"has filed an initial Form 3 reporting his ownership"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"represents his beneficial holdings as disclosed in the Form 3"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What does the DR REDDYS LABORATORIES (RDY) Form 3 filing show?
The Form 3 shows an initial ownership report by Milan Kantilal Kalawadia, CEO – North America. It discloses direct ownership of 47,325 Equity Shares underlying ADRs, establishing his baseline stake without indicating any recent share purchases or sales.
Is the RDY Form 3 a buy or sell transaction?
The RDY Form 3 is not a buy or sell transaction. It is an initial ownership statement listing 47,325 Equity Shares underlying ADRs held directly by Milan Kantilal Kalawadia, providing a baseline for his stake rather than reporting new trading activity.
Who is the insider in the DR REDDYS LABORATORIES (RDY) Form 3 filing?
The insider is Milan Kantilal Kalawadia, who serves as CEO – North America for DR REDDYS LABORATORIES. The Form 3 records his direct ownership of 47,325 Equity Shares underlying ADRs, giving investors visibility into his reported equity position with the company.